AbbVie Acquires Apogee Therapeutics For $10.9 Billion To Enhance Immunology Portfolio

AbbVie has agreed to acquire Apogee Therapeutics for $10.9 billion in equity value. This transaction is one of the largest pharmaceutical acquisitions of 2026 and is expected to enhance AbbVie’s immunology portfolio by incorporating zumilokibart, a clinical-stage therapy aimed at treating inflammatory diseases like atopic dermatitis and asthma. The acquisition aligns with AbbVie’s strategy to mitigate competitive pressures following the expiration of exclusivity for Humira and to address rising competition in the immunology sector from companies such as Johnson & Johnson.

Summary of transaction details:

• Deal Type: Acquisition
• Transaction Amount: $10,900,000,000
• Acquiring Company: AbbVie
• Target Company: Apogee Therapeutics
• Founder of Target Company: Michael Henderson
• Headquarters of Target Company: Waltham, Massachusetts

Apogee Therapeutics, founded by Michael Henderson, has developed innovative therapies focusing on inflammatory diseases. The acquisition by AbbVie is indicative of their commitment to strengthening their pipeline in immunology. No notable investors were mentioned in the provided context.